100% sensitivity with two accelerated diagnostic pathways for ruling out acute myocardial infarction

In a study of 1,811 patients who presented to the emergency department (ED), high-sensitivity troponin I was measured with presentation and 2-hour blood samples to find the accuracy and performance of five accelerated chest pain pathways calculated with the Access hsTnI (High Sensitivity Troponin I) Assay. Patients were then classified as being low risk according to five rules: modified accelerated diagnostic protocol to assess patients with chest pain symptoms using troponin as the only biomarker (m-ADAPT); the Emergency Department Assessment of Chest Pain Score (EDACS) pathway; the History, ECG, Age, Risk Factors, and Troponin (HEART) pathway; the No Objective Testing Rule; and the new Vancouver Chest Pain Rule. Endpoints were 30-day acute myocardial infarction and acute coronary syndrome. Measures of diagnostic accuracy for each rule were calculated.

The study concluded:

The new Vancouver Chest Pain Rule and No Objective Testing Rule had high sensitivity for acute myocardial infarction (100% for both) and acute coronary syndrome (98.6% and 99.3%)
The m-ADAPT, EDACS, and HEART pathways also yielded high sensitivity for acute myocardial infarction (96.9% for m-ADAPT and 95% for EDACS and HEART)
Using the Access hsTnI Assay with the new Vancouver Chest Pain Rule or No Objective Testing Rule enabled approximately one third of patients to be safely discharged after 2-hour risk stratification with no further testing
The EDACS, m-ADAPT, or HEART pathway enabled half of ED patients to be rapidly referred for objective testing

At a Glance

1811

Patients who presented to an ED in Australia

1 /2

Of ED patients able to be rapidly referred for objective testing with the EDACS, m-ADAPT or HEART pathway

100 %

Sensitivity for acute myocardial infarction using the new Vancouver Chest Pain Rule or the No Objective Testing Rule

To Read The Full Study: Click Here

Source: Greenslade, J. H., Carlton, E. W., Van Hise, C., Cho, E., Hawkins, T., Parsonage, W. A., Tate, J., Ungerer, J., & Cullen, L. (2018). Diagnostic Accuracy of a New High-Sensitivity Troponin I Assay and Five Accelerated Diagnostic Pathways for Ruling Out Acute Myocardial Infarction and Acute Coronary Syndrome. Annals of Emergency Medicine, 71(4), 439–451.e3. https://doi.org/10.1016/j.annemergmed.2017.10.030

Information addressed to health professionals. The products presented on this site are for professional use only, and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

© 2024 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

U.S. Government Users Restricted Rights - As per GSA ADP Schedule Contract with Beckman Coulter, Inc., the use, duplication or disclosure is restricted as follows: Beckman Coulter hereby authorizes user to copy those documents published on the World Wide Web by Beckman Coulter, for noncommercial use, and only within the user's organization. Except as expressly provided above, nothing contained herein shall be construed as granting any license or right under any Beckman Coulter copyright. Nothing contained herein shall be construed as granting by implication, estoppel or otherwise any license or right under any patent or trademark of Beckman Coulter or any third party.

Choose your country/region and language

Country or Region

Language

100% sensitivity with two accelerated diagnostic pathways for ruling out acute myocardial infarction

At a Glance

To Read The Full Study: Click Here